The US Food and Drug Administration recently granted licensing approval for Grifols to commercialize a range of antisera reagents designed for routine and complex immunohematology testing.
Manual techniques for blood typing and pretransfusion testing continue to be a large segment in the US blood transfusion industry.
To meet the growing demand for innovative blood typing solutions, Grifols comprehensive portfolio now includes ABO and Rh monoclonal antisera, rare antigen antisera, and anti-human globulin sera. Most of these reagents require no incubation time.
Grifols is producer of plasma-derived medicines and provider of a variety of postexposure prophylaxis and immune globulin products for patients. Its three main divisions--bioscience, diagnostic, and hospital--develop, produce, and market innovative products and services that are available in more than 100 countries.
The company has approximately 18,000 employees in 30 countries.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval